HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

USNA

USANA Health Sciences, Inc. (NYSE)

Consumer Defensive — Packaged Foods

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.

None 1 analysts
$22.16
+$0.04 (+0.18%)
Target: $39.00 (76.0%)
Sign in to add USNA to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$401.02M
P/E Ratio (TTM)43.44
Forward P/E7.84
EPS (TTM)$0.50
Dividend Yield-
Profit Margin0.96%
Revenue Growth0.30%
ROE1.55%
Debt/Equity2.35
Recommendation None
Analyst Target$39.00
Analysts1
Indexes NYSE

Technical Indicators

RSI (14)70.9
Beta0.73
SMA 20-
SMA 40-
52-Week High$38.32
52-Week Low$16.60
50-Day Avg$18.96
200-Day Avg$20.38
Avg Volume110.3K
Volume67.5K

Performance Analysis

NEUTRAL

USNA presents a mixed picture with both positive and negative indicators.

~ Trading at 26% of its 52-week range.
- RSI at 70.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 43.4 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 0.3% year-over-year.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $39.00 implies 76.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:36 UTC

Back to Screener Export Report